Articles tagged with Prostate Cancer
Researchers at the University of Southern California have identified a common genetic risk factor for colorectal and prostate cancer. The study found that one variant previously associated with prostate cancer also increases the risk of developing colorectal cancer.
A new drug candidate, abiraterone, has shown significant anti-tumor activity in early trials for patients with advanced prostate cancer whose tumors have continued to grow despite medical or surgical castration. The drug reduced PSA levels and shrunk tumors in both pre- and post-chemotherapy patients.
A diet rich in omega-3 fatty acids found to reduce prostate tumor growth and increase survival in genetically predisposed mice. Omega-6 fatty acids had the opposite effects, highlighting a beneficial interaction between genes and diet.
Research suggests that a diet high in omega-3 fatty acids may improve prognosis for men genetically prone to develop prostate cancer. The study found that mice with a genetic defect causing prostate cancer had reduced tumor growth, slowed disease progression and increased survival when fed a high-omega-3 diet.
Researchers at Rutgers and Penn are developing advanced imaging techniques to increase the accuracy of prostate cancer diagnoses. These methods use powerful MRI and computer-aided diagnosis tools to reveal previously hidden cancerous tissue and pinpoint concentrations of suspicious tissue.
A recent review examines the evidence supporting PSA testing for prostate cancer screening. Despite controversy over its effectiveness, many Canadian men are being tested due to widespread practice. The article also discusses finasteride's potential in reducing enlarged prostate risks and cancer risk.
BRCA2 mutation carriers have a higher risk of developing aggressive and lethal prostate cancer, with younger onset and advanced-stage disease, according to a study published in the Journal of the National Cancer Institute. The study suggests that studying gene expression patterns in prostate cancers may help predict progression.
Researchers at Institut Gustave Roussy found that a combination of radiation and angiogenesis inhibitors can overcome HIF-1–dependent tumor radioresistance in mice. This breakthrough suggests a new approach to treating cancer by shifting tumor resistance towards apoptosis, according to the study published online on June 7.
A trial found that circulating tumor cells in the blood of patients with metastatic prostate cancer can predict how well they will respond to chemotherapy. Patients with more than five tumor cells per blood sample had a worse prognosis, while those whose CTC number went down fared better.
A study from the University of Chicago Medical Center found that African-American men radically underestimate the likelihood of a cancer diagnosis after a needle biopsy for suspected prostate cancer. This underestimation can lead to delayed diagnoses and poorer outcomes.
A new study reveals that patients with localized prostate cancer are more likely to receive surgery if they see a urologist, while those who see a radiation oncologist and urologist tend to receive radiation therapy. The study suggests that men should seek a balanced perspective on treatment options from specialists.
The OHSU Cancer Institute study found that sipuleucel-T vaccine slowed the rate of rise of serum PSA in exploratory analyses, but did not significantly delay cancer progression. The treatment also showed a favorable safety profile with common side effects like fatigue and chills.
Researchers found that radium-223 significantly reduced levels of bone alkaline phosphatase, a marker for HRPC progression, by 66% and prolonged median survival time by 41 weeks. However, treatment had no significant effect on skeletal-related events.
A new study developed a simple marker that allows urologists to identify men at risk for high-grade prostate cancer, even after a negative initial biopsy. This finding could reduce overtreatment and unnecessary biopsies while improving patient outcomes.
Researchers have identified C-reactive protein (CRP) as a strong indicator of survival for men with advanced prostate cancer. The study found that higher levels of CRP are associated with shorter survival and lower response to chemotherapy.
A study found that men with a high rate of increase in prostate-specific antigen (PSA) levels before treatment have a higher risk of death from prostate cancer. Elevated PSA velocity was a stronger predictor of poor prognosis than other single indicators, such as biopsy Gleason scores or advanced disease categories.
Researchers found a strong correlation between initial PSA levels and future diagnosis of advanced disease. Men with high PSA levels had a higher risk of developing advanced disease, emphasizing the importance of early testing.
A recent study has discovered a strong hereditary component to aggressive prostate cancer, with patients carrying the 8q24 genetic marker having a higher risk of developing the disease. The marker is twice as common in African-American men, who also experience the disease at a younger age and have a higher incidence rate.
Researchers found a direct correlation between statin use and decreased prostate-specific antigen levels, as well as lower mortality rates from prostate cancer. The study suggests that increased statin use may be contributing to declining prostate cancer mortality rates in the US between 1993 and 2003.
Researchers have found that veterans exposed to Agent Orange have a 48% higher risk of prostate cancer recurrence following surgery compared to their unexposed peers. Black veterans with a history of exposure were also more likely to experience aggressive disease and rapid PSA level increases.
Researchers found that TRPM8 is expressed in mature, differentiated human prostate primary epithelial luminal cells, but also in prostate cancer cells. The study suggests that inhibiting ER-TRPM8 or PM-TRPM8 may be a potential therapeutic approach for treating prostate cancer. Additionally, the authors propose that blocking aggrecanase...
Researchers found no association between lycopene and prostate cancer prevention, contrary to previous studies. A diet rich in beta-carotene, another antioxidant, was linked to an increased risk of aggressive prostate cancer.
Research suggests that TRPM8 is overexpressed in prostate cancer cells, indicating its potential as a therapeutic target. The study also found that endoplasmic reticulum TRPM8 retains functional activity regardless of cell differentiation status, which may contribute to cancer cell growth.
A web-based program is being tested to help prostate cancer patients make informed treatment decisions by providing information on different approaches. The program aims to reduce inner conflict and increase patient satisfaction.
A study found no association between regular multivitamin use and localized prostate cancer, but an increased risk of advanced prostate cancer among men who took high doses or had a family history. Men taking selenium, beta-carotene, or zinc supplements were also at higher risk.
Researchers at the University of North Carolina Health Care identified protein Ack1 as a trigger for advanced prostate cancer recurrence in men undergoing hormone treatment. This finding may lead to the development of targeted therapies against this protein.
A recent study found that MR imaging can predict prostate cancer recurrence in patients with extracapsular extension. The study, which analyzed 74 men with biopsy-proven prostate cancer, identified features on imaging that indicated a higher risk of metastasis.
A recent study found that MRI and MRS correctly staged 12 out of 16 patients with prostate cancer, enabling surgeons to plan wide resection of the neurovascular bundle. This improved accuracy helps ensure negative surgical margins and effective operations.
Researchers found that high dose radiotherapy (74 Gy) improved cancer control and reduced the need for additional hormone treatment compared to standard radiotherapy (64 Gy). The new conformal radiotherapy method minimized bowel side effects.
The study demonstrates that real-time intra-operative planning consistently achieves optimal coverage of the prostate with minimal doses to healthy structures. This results in improved survival rates and reduced side effects, saving $450 million a year nationwide.
A UCLA study found that three common prostate cancer treatments affect men's lives in different ways, with varying degrees of erectile dysfunction and urinary symptoms. The study tracked 580 men for five years and used a web-based data collection system to gather accurate information.
Researchers found that the androgen receptor plays a key role in bladder cancer development, which explains why it affects men more than women. The discovery opens doors to new treatment options and may help doctors predict tumor recurrence.
The American Association for Cancer Research (AACR) has awarded its inaugural Team Science Award to a multidisciplinary team of researchers from the University of Michigan and Harvard Medical School/Brigham and Women's Hospital. The award recognizes their groundbreaking discovery of gene fusions in prostate cancer, which has significan...
Men with lower educational levels experience a significant drop in quality of life after prostate cancer treatment compared to those with more education. The study controlled for various factors, including income and healthcare access, to show that low education alone is associated with lower quality of life.
A study of 372 men with prostate cancer found that 49% had osteoporosis, with those receiving hormone therapy and having undergone radical prostatectomy being at highest risk. The authors suggest that daily calcium intake could be used as a prognostic factor for osteoporosis in these patients.
Scientists from Wake Forest University School of Medicine found that stress hormone epinephrine can cause changes in prostate and breast cancer cells, making them resistant to cell death. This link between stress and cancer has been suggested but previously unexplored, with potential implications for patients and researchers.
Researchers are investigating a genetically modified variant of Avian Newcastle disease virus to treat human prostate cancer. The virus is designed to replicate only in the presence of prostate-specific antigen, found exclusively in cancerous cells.
A detectable PSA level is first indicator of recurrent prostate cancer after radical prostatectomy, with a doubling time of less than three months indicating imminent death from prostate cancer. Patients with longer doubling times are at significant risk for disease recurrence and cancer-specific death.
New study finds that PSA measurement is associated with prostate cancer prognosis but poorly predicts lethal cancer. Researchers emphasize the need for improved surveillance strategies to identify life-threatening tumors.
A study led by USC and Harvard researchers identified multiple genetic risk factors that predict a man's probability of developing prostate cancer. The findings highlight the importance of this region in prostate cancer, providing potential tools for early screening and prevention efforts.
Researchers, Lucille Sanzero Eller and Elise Lev, are developing a targeted intervention to address physical and psychological symptoms in men with prostate cancer. The study aims to improve quality of life by reducing symptoms such as urinary and bowel incontinence and depression.
Alan Garen and Zhiwei Hu have developed a way to target and destroy tumor blood vessels using nanoparticles. The technology uses a synthetic gene that activates an immune response, allowing for selective destruction of tumors while leaving normal tissue unharmed.
A study by Duke University Medical Center researchers found that obese and overweight men are more likely to have aggressive prostate cancer than biopsy results indicate. This discrepancy may lead to inadequate or inappropriate treatment, emphasizing the need for more accurate biopsies.
A study found that patients who received preventive health exams were more likely to undergo cancer screenings, including colorectal, breast, and prostate cancer testing. The examination may serve as a forum for promoting evidence-based cancer screening.
Cancer researchers have identified a promising compound, ASC-J9, that slows the progression of Kennedy's disease in mice carrying the mutant human gene. The compound breaks up a molecular clog in neurons affected by the disease, improving mobility and muscle function.
A study by Haojie Li and colleagues found that vitamin D deficiency is common among US men, affecting prostate cancer risk. Genetic variations in the VDR gene are also associated with an increased risk of developing prostate cancer.
Research at UCSD School of Medicine suggests inflammation associated with tumor growth plays a key role in prostate cancer metastasis. A signaling pathway triggered by RANK ligand increases metastases in mouse models.
Men diagnosed with obese prostate cancer have a 2.6-fold greater risk of dying compared to normal-weight men with the same profile, regardless of treatment or disease stage. Obesity also significantly increases risk of cancer spreading into distant organs, according to researchers at Fred Hutchinson Cancer Center.
African-American men face significant barriers to timely diagnosis and screening due to constrained healthcare access, distrust of physicians, and socioeconomic disadvantages. The study reveals that knowledge about prostate cancer is comparable to that of white men, but lack of trust in medical care leads to irregular interactions and ...
A study from UNC School of Medicine suggests that improving healthcare access is key to reducing disparities in prostate cancer among black men. The lack of regular healthcare and trust in physicians hindered their ability to receive preventative care, leading to higher death rates.
Dr. John A. Martignetti received a $6.1 million grant to investigate the potential therapeutic role of siRNA in metastatic prostate cancer. The award aims to improve survival and reduce side effects and death for men with advanced prostate cancer.
Researchers at the University of Virginia Health System are investigating molecular therapies for prostate cancer. They plan to identify compensatory pathways and develop combination therapies using a laboratory-made screening approach.
Researchers found that changes in breast density over time can predict a woman's risk of breast cancer, with higher densities linked to greater risks. Meanwhile, targeting prostate-specific proteins may lead to effective treatments for prostate cancer and other diseases, leaving non-prostate cells unharmed.
Men who receive false-positive prostate cancer results experience heightened anxiety about their risk of developing the disease and report issues with sexual function. The study emphasizes the importance of discussing the pros and cons of screening with patients to minimize adverse effects on quality of life.
Researchers found that a combination of green tea polyphenol EGCG and COX-2 inhibitor celecoxib can slow the growth of human prostate cancer. The study demonstrated a synergistic effect, where both agents triggered cellular pathways that were more powerful when combined.
A new study found that androgen deprivation therapy for prostate cancer may increase the risk of death from heart disease in patients over age 65. After adjusting for other cardiovascular risk factors, researchers found a significant link between ADT use and cardiac-related deaths among older men.
A VA researcher has developed a method to identify men at risk for high-grade prostate cancer, reducing the need for unnecessary biopsies. The study found that a high PSA adjusted for prostate size and Gleason scores above 7 indicate a higher risk of life-threatening prostate cancer.
A new class of targeted cancer drugs, pertuzumab, shows promise in slowing the progression of recurrent prostate cancer. The study found that prolonged median survival time was achieved by 16.4 months with the drug compared to 10.7 months in a historical control group.
Scientists have identified a severe form of benign prostatic hyperplasia (BPH) tied to a gene called JM-27. A blood test detects high levels of this protein, indicating more severe symptoms. This discovery could lead to earlier diagnosis and targeted treatment for bladder-related complications.
A University of Illinois study reveals that combining tomatoes and broccoli in the diet can effectively reduce prostate tumors. The study found that eating both foods together produces an additive effect, with tumor cells proliferating more slowly.